Samsung Biologics announced on April 28 that it had signed a 737.3 billion won ($5.4 billion) contract to manufacture pharmaceutical products for a U.S.-based company. This marks its second major order of the year.
In a regulatory filing, the South Korean contract drug manufacturer said the deal, which runs through December 2031, is equivalent to 16.2% of its 2024 consolidated revenue of 4.54 trillion won. The client’s identity will be disclosed only after the agreement expires, due to confidentiality agreements.
The company’s total orders so far this year have reached 2.81 trillion won, more than half — approximately 52% — of its record annual orders of 5.4 trillion won in 2024.
In January, Samsung Biologics signed a 2.07 trillion won contract with a European pharmaceutical company, its largest deal to date. This pushed its cumulative orders to $17.8 billion. In the first quarter alone, the company secured about 40% of last year’s total orders.
